IL2 and synovial sarcoma: Several studies have demonstrated that treatment with low-dose IL-2 increases the number of Treg cells compared to the baseline, decreases the Th17/Treg ratio and improves the symptoms of SS, indicating that IL-2 promotes the proliferation of Treg cells and suggesting that more attention should be paid to immune regulation for the treatment of SS [49].